劉中秋

2003-2006：香港浸會大學中醫藥學院中藥學專業，獲博士學位；

1988-1992：廣州中醫藥大學中藥學院中藥學專業，獲學士學位。

2020-至今：廣州中醫藥大學副校長；

2017-2020：廣州中醫藥大學中藥學院院長；

2013-現今：廣州中醫藥大學國際中醫藥轉化醫學研究所所長；

2007-2013：南方醫科大學藥學院副院長；

2006-2007：香港浸會大學中醫藥學院，博士后；

2004-2005：美國休斯頓大學藥學院藥理藥劑學系，訪問學者；

2003-2006：香港浸會大學博士研究生，博士研究生；

2001-2002：香港中文大學生物系，研究助理；

1992-2003：廣州中醫藥大學新葯開發研究中心，助理研究員。

現兼任廣東省藥學會藥物製劑專業委員會副主任委員等17個學術團隊職務。國際期刊《Pharmacological Research》編輯、《Molecular Pharmaceutics》客座編輯，《中藥材》和《中草藥》雜誌編委。廣東省十一屆和十二屆政協委員。國家百千萬人才工程、有突出貢獻中青年專家，廣東省高等學校珠江學者特聘教授，廣東省領軍人才。

2020年8月，被任命為廣州中醫藥大學副校長，試用1年。

● 影響藥物生物利用度的生理屏障及機理研究

● 基於藥物吸收與代謝原理的新型給葯傳遞系統研究

[1]基於生物利用度屏障的中藥及復方功效評價方法的創新及應用，2019年廣東省科技進步獎一等獎。

[2]抑制細胞增殖與分化異常的新機制研究，2018年度教育部高等學校科學研究優秀成果自然科學獎一等獎。

劉中秋教授長期從事中藥葯代動力學和中藥藥劑學研究。提出了“肝腸三循環”新理論，為中藥功效精準評價和中藥質量研究提供新原理與新方法。國際期刊上發表論文200餘篇， H-Index為38；競爭性獲取縱向科研經費近4000萬元，主持國家自然科學基金課題8項（其中4項為重點項目），國家科技部課題3項，省部級課題10多項；獲廣東省科技進步一等獎、廣東省教學成果二等獎，參獲國家科技進步二等獎、教育部自然科學一等獎等。主編中國醫藥出版社《中藥藥劑學》教材英文版，副主編中國醫藥出版社"十三五"規劃教材和參編人民衛生出版社"十二五"、"十三五"規劃教材《生物藥劑學與葯代動力學》等，參編專著8部。

[1]“解毒-通脈”中藥毛冬青抗心肌缺血再灌注損傷的“多靶點-多成分互作”網路調控機制研究[批准號：81930114]，國家自然科學基金重點項目，297萬元，2020/01-2024/12；

[2]基於體內暴露的中藥附子質量標示物的挖掘、確證與應用[批准號：2017YFE0119900]，中華人民共和國科技部國家重點研發計劃，95萬元，2019/01-2021/12；

[3]肝腸三循環調控黃酮和含黃酮中藥干預結腸癌的分子機制[批准號：81720108033]，國家自然科學基金重點國際（地區）合作研究項目，234萬元，2018.1-2022.12；

[4]益母草鹼的產業化和臨床研究與開發（益母草鹼的臨床葯代研究），[批准號：2017ZX09301002]，中華人民共和國科技部國家科技重大專項，200萬元，2017/01-2020/12，子課題負責人；

[5]中醫藥防治腫瘤轉化醫學研究聯合實驗室，中華人民共和國教育部，2017/01-2019/12。

主持及參與完成的多項科研課題，均以考核優異結題，發表學術論文多篇，其中SCI收錄10餘篇，所承擔本科生教學工作，在教學督導中獲評優秀，指導學生省級創新創業訓練項目2項，校級2項； 指導學生參加課題設計大賽並獲獎，獲得2018年本科生優秀畢業論文指導教師。

[1]. L. Hu, Z. Cao, L. Ma, Z. Liu, G. Liao*, J. Wang*, S. Shen, D. Li, X. Yang*. The potentiated checkpoint blockade immunotherapy by ROS-responsive nanocarrier- mediacted cascade chemo-photodynamic therapy. Biomaterials, 2019, 23, 119469.

[2].Guochao Liao*, Jiatong Guo, Deying Yang, Zhifang Zhou, Zhongqiu Liu, and Zhongwu Guo*. Synthesis of a dimer of the repeating unit of type Ia Group B Streptococcus extracellular capsular polysaccharide and immunological evaluations of related protein conjugates. Org. Chem. Front. 2019, 6, 2833-2838.

[3].Wang LP, Sun RJ, Zhang QS, Luo Q, Zeng SJ, Li XY, Gong X, Li YH, Lu LL, Hu M, Liu ZQ*, An update on polyphenol disposition via coupled metabolic pathways. Expert Opinion on Drug Metabolism & Toxicology, 2019, doi: 10.1080/17425255.2019.1559815.

[4].Li YH, Lu LL, Wang LP, Qu Wei, Liu WQ, Xie YS, Zheng HM, Wang Y, Qi XX, Hu M, Zhu LJ, Liu ZQ, Interplay of Efflux Transporters with Glucuronidation and Its Impact on Subcellular Aglycone and Glucuronide Disposition: A Case Study with Kaempferol. Molecular Pharmaceutics, 2018, 15 (12):5602-5614.

[5].Su T#, Li FY#, Guan JJ, Liu LX, Huan P, Wang Y, Qi XX, Liu ZQ, Lu LL*, Wang DW*. Artemisinin and its derivatives prevent Helicobacter pylori-induced gastric carcinogenesis via inhibition of NF-kappa B signaling. Phytomedicine, 2019, 63

[6].Feng Q#, Wang HJ#, Pang JY, Ji LY, Han JD, Wang Y, Qi XX, Liu ZQ*, Lu LL*. Prevention of Wogonin on Colorectal Cancer Tumorigenesis by Regulating p53 Nuclear Translocation. Frontiers in Pharmacology, 2018, 9: 1356.

[7].Su T#, Yang X#, Deng JH, Huang QJ, Huang SC, Zhang YM, Zheng HM, Wang Y, Lu LL*, Liu ZQ*. Evodiamine, a novel NOTCH3 methylation stimulator, significantly suppresses lung carcinogenesis in vitro and in vivo. Frontiers in Pharmacology, 2018, 9: 434.

[8].Zheng HM#, Huang QJ#, Huang SC, Yang X, Zhu T, Wang WS, Wang HJ, He SG, Ji LY, Wang Y, Qi XX, Liu ZQ*, Lu LL*. Senescence inducer Shikonin ROS-dependently suppressed lung cancer progression. Frontiers in Pharmacology, 2018, 9:519.

[9].He SG#, Ou RL#, Wang WS, Ji LY, Gao H, Zhu YF, Liu XM, Zheng HM, Liu ZQ, Wu P*, Lu LL*. Camptosorus sibiricus rupr aqueous extract prevents lung tumorigenesis via dual effects against ROS and DNA damage. Journal of Ethnopharmacology, 2018, 220:44-56.

[10].Lv SD#, Ji LY#, Chen B, Liu SQ, Lei CY, Liu X, Qi XX, Wang Y, Leung ELH, Wang HY, Zhang L, Yu XM, Liu ZQ*, Wei Q*, Lu LL*. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4. Oncogene, 2018, 37(10):1354-1368.

[11].Wu JJ, Zhu YF, Guo ZZ, Lou YM, He SG, Guan Y, Zhu LJ, Liu ZQ, Lu LL*, Liu L*. Aconitum alkaloids, the major components of Aconitum species, affect expression of multidrug resistance-associated protein 2 and breast cancer resistance protein by activating the Nrf2-mediated signalling pathway. Phytomedicine, 2018, 44:87-97.

[12].Zou J#, Li H#, Huang QL, Liu XM, Qi XX, Wang Y, Lu LL*, Liu ZQ*. Dopamine-induced SULT1A3/4 promotes EMT and cancer stemness in hepatocellular carcinoma. Tumor Biology, 2017, 39(10):1010428317719272.

[13].Kou Y#, Ji LY#, Wang HJ, Wang WS, Zheng HM, Zou J, Liu LX, Qi XX, Liu ZQ, Du BY*, Lu LL*. Connexin 43 upregulation by dioscin inhibits melanoma progression via suppressing malignancy and inducing M1 polarization. International Journal of Cancer, 2017, 141(8):1690-703.

[14].Zhang QS, Zhu LJ, Gong X, Ruan YJ, Yu J, Jiang HY, Wang Y, Qi XX, Lu LL*, Liu ZQ*. Sulfonation disposition of acacetin: in vitro and in vivo. Journal of Agricultural and Food Chemistry, 2017, 65(24):4921-31.

[15].Yu J#, Zhu LJ#, Zheng HH, Gong X, Yu JH, Chen JM, Li YH, Zheng HM, Qi XX, Wang Y, Hu M, Lu LL*, Liu ZQ*. Sulfotransferases and Breast Cancer Resistance Protein Determine the Disposition of Calycosin in Vitro and in Vivo. Molecular Pharmaceutics, 2017, 14(9):2917-2929.

[16].Shi J#, Zhu LJ#, Li Y, Zheng HH, Yu J, Lu LL*, Liu ZQ*. In vitro study of UGT metabolism and permeability of orientin and isoorientin, two active flavonoid C-glycosides. Drug Metabolism Letters, 2016;10(2):101-10.

[17].Liu YT#, Tong YL#, Yang X, Li FY, Zheng L, Liu WQ, Wu JJ, Ou RL, Zhang GY, Hu M, Liu ZQ*, Lu LL*. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer. Pharmacological Research, 2016, 111:113-125.

[18].Zhang GY, Ou RL, Li FY, Wu JJ, Zheng L, Tong YL, Liu YT, Liu ZQ*, Lu LL*. Regulation of drug-metabolizing enzymes and efflux transporters by Astragali radix decoction and its main bioactive compounds: Implication for clinical drug-drug interactions. Journal of Ethnopharmacology, 2016, 180:104-13.

[19].Tong YL#, Liu YT#, Zheng HM, Zheng L, Liu WQ, Wu JJ, Ou RL, Zhang GY, Li FY, Hu M, Liu ZQ*, Lu LL*. Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/b-catenin signaling. Oncotarget, 2016, 7(21):31413-28.

[20].Zheng L#, Zhu LJ#, Zhao M, Shi J, Li YH, Yu J, Jiang HY, Wu JJ, Tong YL, Liu YT, Hu M, Lu LL*, Liu ZQ*. In vivo exposure of kaempferol is driven by phase II metabolic enzymes and efflux transporters. The AAPS Journal, 2016, 18(5):1289-99.

[21].Huang ZY, Huang QJ, Ji LY, Wang Y, Qi XX, Liu L, Liu ZQ*, Lu LL*. Epigenetic regulation of active Chinese herbal components for cancer prevention and treatment: A follow-up review. Pharmacological Research, 2016, 114:1-12.

[22].Wu JJ, Na L, Li FY, Zhang GY, He SG, Zhu YF, Ou RL, Li N, Liu SQ, Feng LZ, Liu L, Liu ZQ, Lu LL*. Induction of P-glycoprotein expression and activity of by aconitum alkaloids: implication for clinical drug–drug interactions. Scientific Reports, 2016, 6:25343.

[23].Wu JJ, Zhu YF, Li FY, Zhang GY, Shi J, Ou RL, Tong YL, Liu YT, Liu L, Lu LL*, Liu ZQ*. Spica prunellae and its marker compound rosmarinic acid induced the expression of efflux transporters through activation of Nrf2-mediated signaling pathway in HepG2 cells. Journal of Ethnopharmacology, 2016, 193:1-11.

[24].Feng LZ#, Huang QJ#, Huang ZY, Li H, Qi XX, Wang Y, Liu ZQ, Liu XH*, Lu LL*. Optimized animal model of Cyclophosphamide-induced bone marrow suppression. Basic & Clinical Pharmacology & Toxicology, 2016, 119(5):428-435.

[25].Shi J, Zheng L, Lin ZF, Hou CQ, Liu WQ, Yan TM, Zhu LJ, Wang Y, Lu LL*, Liu ZQ*. Study of pharmacokinetic profiles and characteristics of active components and their metabolites in rat plasma following oral administration of the water extract of Astragali radix using UPLC-MS/MS. Journal of Ethnopharmacology, 2015, 169:183-194.

[26].Dai PM#, Zhu LJ#, Yang XS, Zhao M, Shi J, Wang Y, Lu LL*, Liu ZQ*. Multidrug resistance-associated protein 2 is involved in the efflux of Aconitum alkaloids determined by MRP2-MDCKII cells. Life Sciences, 2015, 127(2015):66-72.

[27].Wu JJ#, Cheng ZX#, He SG, Shi J, Liu SQ, Zhang GY, Zhu LJ, Liu L, Liu ZQ, Lin N, Lu LL*. Pinelliae rhizoma, a toxic chinese herb, can significantly inhibit CYP3A activity in rats. Molecules, 2015, 20(1):792-806.

[28].Lin ZF, Liu YT, Li FY, Wu JJ, Zhang GY, Wang Y, Lu LL*, Liu ZQ*. Anti-lung cancer effects of polyphyllin VI and VII potentially correlate with apoptosis in vitro and in vivo. Phytotherapy Research, 2015, 29(10):1568-1576.

[29].Liu WQ#, Shi J#, Zhu LJ, Dong LN, Luo FF, Zhao M, Wang Y, Hu M, Lu LL*, Liu ZQ*. Reductive metabolism of oxymatrine is catalyzed by microsomal CYP3A4. Drug Design Development and Therapy, 2015, 9:5771-5783.

[30].Wu JJ#, Cheng ZX#, Chen H, Zhang GY, He SH, Liu SQ, Lin ZF, Zhu LJ, Liu ZQ, Na L*, Lu LL*. The significant inhibition on CYP3A caused by radix Aconiti single herb is not observed in the Wutou decoction: The necessity of combination therapy of radix Aconiti. Journal of Ethnopharmacology, 2015, 170:251-254.